Alvotech FDA Inspection Closes with VAI, Easing Regulatory Overhang at Reykjavik

What happened

Alvotech announced that the FDA closed its May 2026 inspection of the Reykjavik facility with a Voluntary Action Indicated (VAI) classification, the least severe outcome. This marks a notable improvement after prior inspections led to Complete Response Letters for AVT02, AVT04, and AVT05, most recently in November 2025. The VAI status suggests corrective actions have addressed key deficiencies, though it does not guarantee immediate approval of pending applications like AVT05. With over $1 billion in secured debt and a single-site manufacturing platform, this development lowers a major tail risk but does not eliminate execution uncertainty. The news aligns with management’s remediation efforts but must be followed by sustainable product revenue and cash flow to reshape the investment case.

Implication

The successful inspection closure with VAI meaningfully lowers the probability of severe FDA enforcement at Alvotech’s only manufacturing site, easing a key overhang. However, it does not yet ensure smooth approvals for AVT05 or other candidates, nor does it address the company’s high leverage and negative free cash flow. Investors should focus on FY2025 results, AVT05 resubmission timing, and early revenue from European launches of denosumab and aflibercept. Until cash generation and facility reliability are firmly established, the margin of safety remains thin, and the stock could still repricing if subsequent milestones disappoint. We maintain a cautious view, awaiting clearer evidence of durable financial improvement before becoming constructive.

Thesis delta

The FDA’s VAI classification modestly improves the risk-reward profile by reducing the threat of major manufacturing enforcement. Still, the core thesis—that Alvotech’s single-site platform will reliably convert approvals into positive free cash flow and reduce leverage—remains unproven. We adjust our conviction incrementally higher but require further progress on AVT05 and cash flow generation before an upgrade.